The RxPrep Course Book is published annually. Information in the Course Book and Test Banks is up to date at the time of publishing, but drug information can change rapidly. Refer to the Updates on this page for NAPLEX-relevant information that becomes available before the next RxPrep Course Book is published. Guideline updates that may be relevant to NAPLEX are included. If we find anything that needs a correction or clarification in the RxPrep Course Book, it will be included in the Errata table on this page.
Page | Update Type | Description | ||||||
---|---|---|---|---|---|---|---|---|
Chapter 1: Preparing for NAPLEX with RxPrep | ||||||||
p. 12 | Revised NABP NAPLEX Competency Statements Effective January 2021 | NABP has released revised NAPLEX Competency Statements (their blueprint of tested items). Impact for NAPLEX Candidates testing after January 1, 2021:
Comparison of 2020 and 2021 NAPLEX Competency Areas:
Individual Competency Statement wording is different, and often more descriptive and detailed, but the items that will be tested are the same:
| ||||||
p. 12 | NABP NAPLEX Updates Effective January 2021 | The revised NABP Candidate Application Bulletin reflects the following changes:
| ||||||
Chapter 20: Immunizations | ||||||||
p. 330, 331 & 337 | Discontinued Drug | The shingles vaccine Zostavax is no longer available. Continue to recommend the Shingrix vaccine in patients ≥ 50 years. | ||||||
Chapter 24: Infectious Diseases III | ||||||||
p. 412 | Labeling Change | Baloxavir marboxil (Xofluza) has been FDA-approved for post-exposure influenza prophylaxis in patients ≥ 12 years old following contact with an individual who has influenza. It is given as a one-time dose within 48 hours of exposure. | ||||||
Chapter 26: Human Immunodeficiency Virus | ||||||||
p. 426 & 432 | New Drug Approval | Cabotegravir/rilpivirine (Cabenuva) has been FDA-approved for the treatment of HIV in adults. This is an extended-release injectable formulation that is given once monthly as a complete treatment regimen in patients who have been virologically suppressed on a stable regimen. The FDA also approved cabotegravir in a tablet formulation (Vocabria). Oral cabotegravir plus rilpivirine should be given for one month prior to initiation of Cabenuva to assess tolerability. | ||||||
Chapter 39: Common Skin Conditions | ||||||||
p. 576 | Labeling Change | Ivermectin lotion (Sklice) has been FDA-approved to switch from prescription status to over-the-counter (OTC) status. It is indicated as a topical treatment of head lice in individuals 6 months of age and older. Availability is anticipated at the end of the second quarter of 2021. | ||||||
Chapter 41: Asthma and Chapter 42: Chronic Obstructive Pulmonary Disease | ||||||||
p. 598, 612 & 613 | New Drug Approval | A new three-drug combination inhaler, budesonide/formoterol/glycopyrrolate (Breztri Aerosphere), has been approved for COPD. | ||||||
p. 598 | Labeling Change | Umeclidinium/vilanterol/fluticasone (Trelegy Ellipta) has been FDA-approved for maintenance treatment of asthma in patients ≥ 18 years old. | ||||||
Chapter 44: Diabetes | ||||||||
p. 633 | Labeling Change | Dapagliflozin (Farxiga) has been FDA-approved to reduce the risk of cardiovascular death and hospitalization in heart failure with reduced ejection fraction without diabetes. | ||||||
p. 629 & 630 | Guideline Update | The 2021 American Diabetes Association Standards of Care update was published. Key changes that can impact testing include: Comprehensive Care
Treatment for Type 2 Diabetes
| ||||||
Chapter 53: Acute & Critical Care Medicine and Chapter 58: Pain | ||||||||
p. 735 & 778 | New Drug Approval | Oliceridine (Olinvyk) is a new IV opioid agonist approved for moderate to severe acute pain in adults. It is indicated for short-term use in controlled clinical settings (i.e., inpatient or outpatient procedures). |
Page | Description |
---|---|
Chapter 15: Compounding I | |
p. 247 | The section on "Media-Fill Test" should include this statement: "Media-fill testing must be performed initially during training and at least annually for low- and medium-risk level compounding and semiannually for high-risk compounding." |
p. 250 | On the clipboard describing USP 797 cleaning requirements, the minimum frequency of cleaning the walls, windows, shelving, bins, carts, chairs and ceiling should be monthly. |
Chapter 23: Infectious Diseases II | |
p. 389 | In the Study Tip Gal for HAP/VAP: Selecting an Empiric Regimen, the section on “Antibiotics for Pseudomonas (do not use two beta-lactams together)” should include aztreonam. |
Chapter 26: Human Immunodeficiency Virus | |
p. 433 | In the row for Descovy, cross out the statement in the right column. |
p. 436 | The answer key for the fill-in-the-blank quiz should say:
|
Chapter 44: Diabetes | |
p. 629 | The last bullet under Vaccinations should say "Pneumococcal vaccine: Pneumovax 23 (1 dose before age 65)." |
p. 639 | In the Study Tip Gal for Converting Between Insulins, Exception #1 should say "NPH dosed BID → Lantus, Basaglar or Toujeo dosed daily." |
View 2020 RxPrep Course Book Guideline/Drug Updates and Errata
Take your studies with you wherever you go.
Create an account to explore the features of our site, sample our products and take our two FREE Assessment Tests.